insitro and AstraZeneca strike up to $1.5B AI drug-discovery partnership for liver and heart disease

What's the deal? AI drug-discovery company insitro and AstraZeneca announced a collaboration and licensing agreement on 15 October 2026 to use AI to find new drug targets and medicines for two hard-to-treat conditions: MASH (a serious form of fatty liver disease that can lead to cirrhosis) and cardiomyopathy (a disease of the heart muscle). The deal includes a $40 million upfront payment to insitro, with up to approximately $1.46 billion in development and commercial milestones, plus single-digit royalties on any products that reach the market.

Why it matters: The partnership puts insitro's machine-learning platform at the front of AstraZeneca's early drug discovery. Both diseases are driven by complex biology where patients vary widely, and both companies argue that AI trained on large human and cellular datasets can spot the drivers of disease that conventional approaches miss. AstraZeneca takes exclusive global rights to advance any selected programmes, and will lead clinical development, regulatory work and commercialisation. For insitro, founded by Daphne Koller in 2018 with a focus on using machine learning to de-risk drug development, it is another large pharma collaboration alongside existing relationships with Bristol Myers Squibb and Eli Lilly.

The mechanism: insitro will apply its Virtual Human platform, which combines large-scale human and cellular data with AI-enabled target identification and medicine design, to nominate targets in MASH and cardiomyopathy. AstraZeneca then takes over from target selection through to development. Neither company disclosed how many targets are involved or the timeline.

Read more: AstraZeneca, 15 October 2026 · FirstWord Pharma, 15 October 2026